• Cinoxacin: Redefining Gram-Negative Infection Research

  2026-07-23

  Explore how Cinoxacin, a quinolone antibiotic from APExBIO, is transforming the landscape of translational research targeting Gram-negative bacterial infections. This thought-leadership article delivers mechanistic insights, experimental strategies, and competitive benchmarking, while elevating the discussion beyond standard product pages with forward-thinking guidance for urinary tract infection and antibiotic resistance studies.

• BMS-345541 Hydrochloride: Precision IKK Inhibitor Protocols

  2026-07-23

  BMS-345541 hydrochloride delivers precise, selective IKK inhibition for inflammation and cancer biology research, optimizing workflows targeting NF-κB-dependent pathways. This guide provides actionable protocol parameters, troubleshooting strategies, and cross-study insights to help researchers maximize assay success.

• Dutasteride as a Dual 5-Alpha-Reductase Inhibitor: Advanced

  2026-07-22

  Dutasteride enables high-precision modeling of androgen-driven mechanisms in prostate cancer and BPH research. This article provides actionable workflow enhancements, protocol specifics, and troubleshooting tips, leveraging APExBIO’s rigorously characterized compound for robust, reproducible results.

• Mavorixafor in WHIM Syndrome: Phase 3 Trial Advances & Impli

  2026-07-22

  A recent placebo-controlled phase 3 trial demonstrates that mavorixafor, an oral CXCR4 antagonist, significantly improves neutrophil and lymphocyte counts and reduces infection rates in patients with WHIM syndrome. This study represents a critical step toward targeted therapy for this rare combined immunodeficiency, offering new benchmarks for clinical trial design and patient management.

• Inhaled Risedronate Sodium Microspheres Target Emphysema via

  2026-07-21

  The referenced study introduces a novel inhalable Risedronate Sodium-chitosan microsphere formulation, demonstrating targeted deposition in the alveolar region and induction of apoptosis in alveolar macrophages to attenuate pulmonary emphysema. This innovation provides mechanistic insight and a foundation for repurposing bisphosphonates in respiratory disease models, with implications for advanced drug delivery strategies.

• Doxycycline Hyclate as a Matrix Metalloproteinases Inhibitor

  2026-07-21

  Doxycycline hyclate stands out as a research-grade matrix metalloproteinases inhibitor, offering robust protection of blood-brain barrier integrity in neurovascular models. Its validated performance, high solubility, and multi-domain applications make it indispensable for researchers tackling vascular, infectious, and inflammatory pathologies.

• Lactate-GPR81-FARP1-Rac1 Axis Enables Insulin-Independent Gl

  2026-07-20

  This study uncovers a lactate-driven, insulin-independent signaling pathway in skeletal muscle that enhances glucose uptake via GPR81-mediated Rac1 activation. The findings provide mechanistic insights into metabolic adaptations during exercise and suggest new therapeutic targets for hyperglycemia.

• Mavorixafor in WHIM Syndrome: Phase 3 Outcomes and Research

  2026-07-20

  The referenced phase 3 trial demonstrates that mavorixafor, an oral CXCR4 antagonist, effectively increases neutrophil and lymphocyte counts while reducing infection rates in WHIM syndrome patients. This study marks a significant advance in targeted therapy for rare immunodeficiencies and sets a new benchmark for clinical trial rigor in orphan diseases.

• Açaí Extracts: Cytotoxicity and Enzyme Induction in Hepatocy

  2026-07-19

  Raichura et al. present a comprehensive in vitro evaluation of açaí (Euterpe oleracea) extracts on human hepatocyte viability and the modulation of key drug-metabolizing enzymes and transporters. Their findings highlight limited induction potential but underscore dose-dependent cytotoxicity, refining the risk assessment for botanical-drug interactions in hepatocyte models.

• Applied Workflows with Murine Recombinant PDGF-BB: Protocols

  2026-07-18

  PDGF-BB, murine recombinant protein, is the gold standard for driving reproducible cell proliferation and advanced vascular remodeling assays. This article dissects hands-on experimental workflows, troubleshooting strategies, and the translational relevance of PDGF-BB’s mitogenic activity, leveraging recent breakthroughs in pulmonary hypertension research.

• Angiotensin Peptides Modulate SARS-CoV-2 Spike–AXL Interacti

  2026-07-17

  This study demonstrates that specific angiotensin peptides, particularly truncated forms of angiotensin II, enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. These findings reveal an unexpected cross-talk between the renin-angiotensin system and viral entry mechanisms, with implications for understanding COVID-19 pathogenesis and therapeutic targeting.

• Niclosamide: STAT3 Pathway Inhibition and Cancer Research Ut

  2026-07-17

  Niclosamide, a small-molecule STAT3 inhibitor (IC50: 0.7 μM), induces G0/G1 cell cycle arrest and apoptosis in cancer models. Its dual inhibition of STAT3 and NF-κB pathways supports advanced cancer research, with proven in vitro and in vivo efficacy. APExBIO's B2283 formulation is widely adopted for STAT3 signaling studies.

• Liproxstatin-1: Optimizing Ferroptosis Inhibitor Workflows

  2026-07-16

  Liproxstatin-1 is a benchmark ferroptosis inhibitor, enabling precise inhibition of lipid peroxidation in both cellular and animal models. This article provides stepwise protocols, troubleshooting guidance, and insights into sex-specific ferroptosis mechanisms, empowering researchers to achieve robust, reproducible results in advanced ferroptosis research.

• Glucocorticoid Suppression of CaV1.2 via Kv2.1 and PKA in Hi

  2026-07-16

  This study reveals that glucocorticoids rapidly suppress CaV1.2-mediated calcium signals in hippocampal neurons by promoting endocytosis of Kv2.1 channel clusters through cAMP/PKA pathway inhibition. These findings clarify a nongenomic mechanism for stress hormone action in the brain and highlight new targets for modulating neuronal excitability.

• MMP-2/9-Mediated BBB Disruption in Arsenic-Induced Cognitive

  2026-07-15

  This study defines how sodium arsenite exposure impairs learning and memory in male mice by promoting MMP-2 and MMP-9-mediated blood-brain barrier (BBB) disruption and neuronal apoptosis. Doxycycline hyclate, as a matrix metalloproteinases inhibitor, preserved BBB integrity and improved cognitive outcomes, highlighting key mechanistic targets for neurotoxicity research.

16804 records 1/1121 page Next 12345 下5页 Last page